Intervention

QL1101

ClinicalTrials.gov intervention label

Clinical trials2

Recruiting0

Common conditions2

Lead sponsors shown1

Clinical trials

2 shown

Efficacy and Safety of QL1101 and Avastin® Respectively Combined With Paclitaxel and Carboplatin in the First-line Treatment of Non-squamous Non-small Cell Lung CancerNCT03169335 · 2017-03-28

To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in Study of QL1101 and Avastin® in Patients With Non-squamous Non-small Cell Lung CancerNCT03195569 · 2017-03-01

Common conditions

Non Small Cell Lung Cancer1 Non-squamous Non-small Cell Lung Cancer1

Leading sponsors

Qilu Pharmaceutical Co., Ltd.2

Trial status mix

COMPLETED1

UNKNOWN1

Phase mix

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.